Medtronic plc MDT
NYSEMedical devicesFinancials to Jul 31, 2026 · Updated Nov 11, 2026
Moat ranks
Balance sheet
| $B | Apr 24 | Jul 31 |
|---|---|---|
| Cash | 1.9 | 1.7 |
| Securities | 7.3 | 7.1 |
| Debt | 27.9 | 28.2 |
| Net cash | -18.6 | -19.3 |
| Equity | 49.5 | 50.2 |
- Debt / EBITDA
- 2.89×
- Debt / equity
- 0.56×
- Leases (4/24/26)
- $1.2B
- Diluted shares
- 1,285M
- Book value / share
- $39.09
- Price / book
- –
- Net cash / share
- −$15.02
- Market cap
- –
- Enterprise value
- –
Per-share record
Key indicators
| Indicator | Latest | Vs year ago | Last 8 quarters |
|---|---|---|---|
| Revenue growth | 13.7% | +5.4 pts | |
| Operating margin | 18.1% | +1.2 pts | |
| FCF margin | 13.2% | +6.4 pts | |
| Capex / revenue | 5.2% | -0.7 pts | |
| Global CGM attachment rate | 69.0% | +5.0 pts | |
| Cardiac Ablation Solutions revenue growth | +88% | +38 pts | |
| New insulin pumps sold (quarter) | ~34,000 | +6% | |
| Cranial and Spinal Technologies revenue (quarter) | $1.4B | +13% | |
| Surgical and Endoscopy revenue (quarter) | $1.7B | +9% |
Margins and growth from reported quarters; company KPIs as reported in results releases.
About MDT
Medtronic sells cardiac implants and ablation tools, spine and neurosurgical platforms, surgical instruments and monitoring devices. Clinical training, connected workflows and installed-system consumables provide selective protection.
- Data Workflow Lockin
Implanted cardiac devices and remote monitoring put Medtronic in repeated clinic workflows.
- Training Org Change Costs
Physicians and lab staff learn Medtronic catheters, mapping software and procedure protocols.
- Training Org Change Costs
Surgeons and operating-room teams learn Medtronic imaging, navigation, robotic guidance and implants together.
- Data Workflow Lockin
AiBLE connects planning, imaging, navigation and robotic guidance in the operating room.
- Oct 15, 2026
Medtronic completed the MiniMed split-off and retains no ownership. Removed former Diabetes moat claims from current scoring and rebased retained-portfolio revenue weights on FY2026 reported sales; retained historical financial/KPI scope pending issuer recast.
- Oct 7, 2026
Medtronic published a final exchange ratio of 4.5939 MiniMed shares per accepted Medtronic share, with the upper limit in effect. The cap reduces the pricing incentive; completion and Medtronic shares retired remain pending before the scheduled October 9 expiry.
- Oct 1, 2026
Medtronic announced Category I procedure-code approvals for Altaviva and Symplicity, effective January 2028. Codes support payment pathways but do not guarantee coverage.
- Sep 30, 2026
Medtronic announced Affera mapping software clearances and a PulseSelect proximity-software CE Mark, expanding ablation workflow capabilities.
- Sep 24, 2026
Medtronic recalled SmartSync/CareLink products in Canada for a Micra remaining-life calculation error, adding a cardiac software remediation need.
Ownership
Go deeper on MDT
- Compare stock research toolsFundamentals, valuation and screening platforms for MDT.19 tools
- See MDT's price chartNo price chart here yet. See price history and indicators.17 tools
- Read MDT's earnings callsTranscripts and audio of results calls, with management's own words.15 tools
- Investing tool dealsCurrent discounts on research, charting and tracking tools.98 deals
On this page
Financial record
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | Trend | Change 2017–26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Per share ($) | |||||||||||||
| Revenue | 21.35 | 21.89 | 22.51 | 21.40 | 22.24 | 23.45 | 23.43 | 24.33 | 26.00 | 28.23 | 29.21 | +3.2%/yr | |
| Cash flow | 4.94 | 3.42 | 5.16 | 5.35 | 4.61 | 5.44 | 4.53 | 5.10 | 5.46 | 5.69 | 6.25 | +1.6%/yr | |
| Earnings | 2.89 | 2.27 | 3.41 | 3.54 | 2.66 | 3.73 | 2.82 | 2.76 | 3.61 | 3.73 | 4.07 | +2.8%/yr | |
| Free cash flow | 4.04 | 2.64 | 4.33 | 4.46 | 3.61 | 4.42 | 3.44 | 3.91 | 4.02 | 4.21 | 4.77 | +0.5%/yr | |
| Capex | 0.90 | 0.78 | 0.84 | 0.90 | 1.00 | 1.01 | 1.09 | 1.19 | 1.44 | 1.48 | 1.48 | +5.7%/yr | |
| Dividends | 1.71 | 1.82 | 1.98 | 2.14 | 2.30 | 2.50 | 2.71 | 2.76 | 2.78 | 2.83 | 2.84 | +5.8%/yr | |
| Book value | 36.08 | 37.07 | 36.90 | 37.55 | 37.98 | 38.89 | 38.63 | 37.75 | 37.23 | 38.40 | 39.09 | +0.7%/yr | |
| Diluted shares (M) | 1,391 | 1,368 | 1,358 | 1,351 | 1,354 | 1,351 | 1,333 | 1,330 | 1,290 | 1,288 | 1,285 | -0.9%/yr | |
| Totals ($B) | |||||||||||||
| Revenue | 29.7 | 30.0 | 30.6 | 28.9 | 30.1 | 31.7 | 31.2 | 32.4 | 33.5 | 36.4 | 37.5 | +2.3%/yr | |
| Operating income | 5.4 | 6.6 | 6.3 | 4.8 | 4.5 | 5.8 | 5.5 | 5.1 | 6.0 | 6.5 | 6.8 | +2.1%/yr | |
| Net income | 4.0 | 3.1 | 4.6 | 4.8 | 3.6 | 5.0 | 3.8 | 3.7 | 4.7 | 4.8 | 5.2 | +2.0%/yr | |
| Free cash flow | 5.6 | 3.6 | 5.9 | 6.0 | 4.9 | 6.0 | 4.6 | 5.2 | 5.2 | 5.4 | 6.1 | -0.4%/yr | |
| Buybacks | 3.5 | 2.2 | 2.9 | 1.3 | 0.7 | 2.5 | 0.6 | 2.1 | 3.2 | 1.0 | 1.2 | -12.8%/yr | |
| Dividends | 2.4 | 2.5 | 2.7 | 2.9 | 3.1 | 3.4 | 3.6 | 3.7 | 3.6 | 3.6 | 3.7 | +4.9%/yr | |
| Net cash | -19.6 | -14.3 | -15.4 | -13.8 | -15.5 | -13.4 | -16.3 | -16.9 | -19.5 | -18.6 | -19.3 | +$0.9B | |
| Margins & returns (%) | |||||||||||||
| Gross margin | 68.7 | 69.8 | 70.0 | 67.4 | 65.2 | 68.0 | 65.7 | 65.3 | 65.3 | 65.0 | 65.0 | -3.7 pts | |
| Operating margin | 18.1 | 22.2 | 20.5 | 16.6 | 14.9 | 18.2 | 17.6 | 15.9 | 17.8 | 17.8 | 18.1 | -0.3 pts | |
| Net margin | 13.6 | 10.4 | 15.2 | 16.6 | 12.0 | 15.9 | 12.0 | 11.4 | 13.9 | 13.2 | 13.9 | -0.4 pts | |
| FCF margin | 18.9 | 12.1 | 19.2 | 20.8 | 16.2 | 18.9 | 14.7 | 16.1 | 15.5 | 14.9 | 16.3 | -4.0 pts | |
| ROIC | 6.3 | 8.3 | 7.8 | 6.1 | 5.5 | 7.1 | 6.6 | 6.3 | 7.2 | 7.8 | 8.0 | +1.5 pts | |
| Return on equity | 8.0 | 6.1 | 9.2 | 9.4 | 7.0 | 9.6 | 7.3 | 7.3 | 9.7 | 9.7 | 10.4 | +1.7 pts | |
| R&D % of revenue | 7.4 | 7.5 | 7.6 | 8.1 | 8.3 | 8.7 | 8.6 | 8.5 | 8.1 | 7.9 | 7.8 | +0.5 pts | |
| Stock pay % of revenue | 1.2 | 1.1 | 0.9 | 1.0 | 1.1 | 1.1 | 1.1 | 1.2 | 1.3 | 1.3 | 1.3 | +0.1 pts | |
| Capex % of revenue | 4.2 | 3.6 | 3.7 | 4.2 | 4.5 | 4.3 | 4.7 | 4.9 | 5.5 | 5.2 | 5.1 | +1.0 pts | |
Change uses 2017 and 2026 only: compound annual growth for amounts, points for margins and returns, and the change in amount for net cash. A dash means no 2017 base. Trend shows the fiscal years.
Moat
Moat scorecard
- Strength
- Confidence
- Structure
- Oligopoly
- Durability
- medium
- Trajectory
- stable
- Pricing power
- moderate
- Cardiovascular Portfolio42.0%2 claims
- Neuroscience Portfolio30.9%2 claims
- Medical Surgical Portfolio26.5%1 claim
- Former Diabetes / MiniMed (separated October 2026)0.0%No moat
Moat claims
- Applies to
- Cardiovascular Portfolio
- Confidence
- Durability
- medium
- Trajectory
- stableas of Oct 7, 2026
Implanted cardiac devices and remote monitoring put Medtronic in repeated clinic workflows. Replacing a monitoring vendor requires staff changes and patient transfer; it does not make future implants exclusive. Software reliability is part of the protection.
Remote monitoring remains embedded, but the CareLink software recall shows that installed use also creates quality obligations. No public clinic-retention series shows wider protection.
- Cardiac Rhythm and Heart Failure revenue (fiscal year)$7.5B+17%
- Cardiac Rhythm and Heart Failure revenue (quarter)$2.1B+22%
- Electrophysiology Therapies revenue (quarter)$2.2B+30%
- Vendor-neutral monitoring platforms and interoperability requirements
- Cybersecurity incidents reducing adoption of connected services
- Errors in battery-life estimates can damage clinical trust and require software corrections.
- FilingFY2026 Form 10-K - Cardiovascular remote monitoring products and servicesJun 18, 2026
- SourceHealth Canada CareLink SmartSync recallOct 1, 2026
- Applies to
- Cardiovascular Portfolio
- Confidence
- Durability
- durable
- Trajectory
- wideningas of Oct 8, 2026
Physicians and lab staff learn Medtronic catheters, mapping software and procedure protocols. This training makes switching costly, while strong competing clinical results can still move purchasing decisions.
Cardiac Ablation Solutions organic sales grew 88% in Q1 FY2027, which included an extra week. That supports adoption alongside earlier reported share gains, while new rival catheters still contest the workflow.
- Cardiac Rhythm and Heart Failure revenue (fiscal year)$7.5B+17%
- Cardiac Ablation Solutions revenue growth+88%
- Cardiac Rhythm and Heart Failure revenue (quarter)$2.1B+22%
- Electrophysiology Therapies revenue (quarter)$2.2B+30%
- Hospital consolidation and centralized purchasing reducing physician influence
- Tender-based procurement emphasizing price
- A delivery-catheter recall can interrupt valve procedures and weaken hospital trust in the wider cardiovascular portfolio.
- FilingFY2025 Form 10-K (Item 1: Business - Sales and Distribution)Jun 20, 2025
- NewsMedtronic cardiac mapping software approvalsSep 30, 2026
- ResultsMedtronic Q3 FY2026 prepared commentaryFeb 17, 2026
- NewsAbbott FDA approval of TactiFlex DuoSep 8, 2026
- Applies to
- Neuroscience Portfolio
- Confidence
- Durability
- durable
- Trajectory
- stableas of Oct 7, 2026
Surgeons and operating-room teams learn Medtronic imaging, navigation, robotic guidance and implants together. Replacing an established spine platform requires training and workflow changes, but hospitals can buy competing systems.
The installed spine workflow remains valuable. New Stealth AXiS tools and stronger enabling-technology sales support adoption, but public procedure-use and retention figures remain limited.
- Cranial and Spinal Technologies revenue (fiscal year)$5.2B+5%
- Cranial and Spinal Technologies revenue (quarter)$1.4B+13%
- Hospital capital spending slowdowns delaying platform refresh cycles
- Competing robotics/navigation ecosystems displacing incumbents
- FilingFY2026 Form 10-K - Cranial & Spinal Technologies integrated portfolioJun 18, 2026
- FilingGlobus Medical FY2025 Form 10-K, connected navigation ecosystemFeb 24, 2026
- Applies to
- Neuroscience Portfolio
- Confidence
- Durability
- medium
- Trajectory
- stableas of Oct 7, 2026
AiBLE connects planning, imaging, navigation and robotic guidance in the operating room. Integrated procedure data and equipment interfaces make a replacement project harder. This is workflow integration; the public evidence does not establish a third-party network effect.
Integrated tools remain useful, but Globus offers a comparable planning, imaging and navigation ecosystem. Higher equipment sales do not yet establish stronger retention or recurring implant attachment.
- Cranial and Spinal Technologies revenue (fiscal year)$5.2B+5%
- Cranial and Spinal Technologies revenue (quarter)$1.4B+13%
- Open interoperability reducing value of a single-vendor ecosystem
- Competitors bundling comparable ecosystems at lower total cost
- FilingFY2025 Form 10-K (Item 1: Business - Cranial & Spinal Technologies)Jun 20, 2025
- NewsMedtronic Q1 FY2027 resultsSep 1, 2026
- ResultsMedtronic Q3 FY2026 prepared commentaryFeb 17, 2026
- FilingGlobus Medical FY2025 Form 10-K, connected navigation ecosystemFeb 24, 2026
- Applies to
- Medical Surgical Portfolio
- Confidence
- Durability
- medium
- Trajectory
- stableas of Oct 7, 2026
LigaSure energy platforms and Hugo robotic systems use dedicated instruments for repeated procedures. The September U.S. clearance expands LigaSure instruments on Hugo. This supports a limited installed-system consumables claim; it does not protect the whole surgical and monitoring portfolio.
The new LigaSure clearance expands the product range. Hugo utilization and repeat-instrument attachment are still undisclosed, while Intuitive’s installed systems and procedures continue to grow.
- Surgical and Endoscopy revenue (fiscal year)$6.8B+4%
- Surgical and Endoscopy revenue (quarter)$1.7B+9%
- Intuitive Surgical has a large established robot base; new hospital systems may choose it instead of Hugo.
- Reprocessed disposables, hospital tenders and competing energy platforms limit repeat-product pricing.
- Low Hugo utilization or recalls can leave installed-system demand below expectations.
- FilingMedtronic FY2026 Form 10-KJun 18, 2026
- NewsFDA clearance of LigaSure RAS Maryland on HugoSep 16, 2026
- FilingIntuitive Q2 2026 earnings releaseJul 16, 2026
Profile change log
- Nov 11, 2026 · business change
Medtronic completed the MiniMed split-off and retains no ownership. Removed former Diabetes moat claims from current scoring and rebased retained-portfolio revenue weights on FY2026 reported sales; retained historical financial/KPI scope pending issuer recast.
- Oct 8, 2026 · analyst revision
Corrected the ventilator exit decision date to February 20, 2024, from a month-only date. The annual filing states the exact decision day.
- Oct 8, 2026 · business change
MiniMed amended its Abbott agreement to add dual glucose-ketone sensors for exclusive integration with its smart dosing systems. The seven-year supply term supports the product pipeline but adds purchase and supplier obligations.
- Oct 8, 2026 · analyst revision
Clarified Abbott sensor compatibility: a seven-year agreement makes Abbott the exclusive third-party sensor supplier for certain MiniMed systems and restricts competing sensor purchases. Added this supplier dependence without changing moat strength or segment evidence status.
- Oct 7, 2026 · business change
Medtronic published a final exchange ratio of 4.5939 MiniMed shares per accepted Medtronic share, with the upper limit in effect. The cap reduces the pricing incentive; completion and Medtronic shares retired remain pending before the scheduled October 9 expiry.
- Oct 7, 2026 · business change
FDA published pediatric postmarket review questions identifying no new safety signals for the Activa Dystonia and Contegra devices and recommending continued routine monitoring. The finding covers those selected devices and is not a portfolio-wide safety conclusion.
- Oct 7, 2026 · analyst revision
Removed combined leader lists from the broad neurological and specialist-device markets because their sources cover different products. Added 2025 worldwide spine concentration and selected FDA pediatric safety reviews without treating either as evidence for the whole portfolio.
- Oct 7, 2026 · analyst revision
Restricted each debate argument to the facts supported by its linked source. Competing robot and spine platforms remain in separate sourced arguments; later-quarter ablation growth and the Cornerstone investment remain in their own records.
- Oct 7, 2026 · analyst revision
Corrected the Bravo timeline to the FDA notice publication date. The source confirms Class I status but does not date the classification decision. Removed repeated recall risk from the debate and kept the cardiac software recall in its claim and market evidence.
- Oct 7, 2026 · analyst revision
Added surviving Blackstone payment guarantees to the separation debate. Selling MiniMed equity does not by itself eliminate all contingent Medtronic cash obligations.
- Oct 7, 2026 · business change
Medtronic recalled certain Harmony valve delivery-catheter lots after tip-detachment risk was found. Retrieval or surgery can be needed during implantation; successfully implanted valves are unaffected.
- Oct 7, 2026 · analyst revision
Changed the spine software and Hugo consumables trajectories from widening to stable. New rival evidence shows competing integrated systems; Medtronic does not yet publish the recurring-use measures needed to establish wider protection. Strength and segment evidence status are unchanged.
- Oct 7, 2026 · analyst revision
Kept estimate-driven tax benefits in reported earnings and added the specific FY2018 intercompany-IP tax benefit. Updated the Puerto Rico tax-case status to the unresolved remand and separated post-July strategic investments from historical acquisition cash flows.
- Oct 7, 2026 · business change
Medtronic announced up to $80 million of Pi-Cardia investments, expected exclusive ShortCut distribution in 2027 and a conditional acquisition option for complex valve procedures.
- Oct 7, 2026 · business change
Medtronic announced its Cornerstone Robotics partnership and paid about $700 million in Q2 FY2027 for a strategic investment and non-U.S. distribution rights.
- Oct 7, 2026 · business change
Medtronic announced Category I procedure-code approvals for Altaviva and Symplicity, effective January 2028. Codes support payment pathways but do not guarantee coverage.
- Oct 7, 2026 · business change
Medtronic announced Affera mapping software clearances and a PulseSelect proximity-software CE Mark, expanding ablation workflow capabilities.
- Oct 7, 2026 · business change
Medtronic recalled SmartSync/CareLink products in Canada for a Micra remaining-life calculation error, adding a cardiac software remediation need.
- Oct 7, 2026 · business change
Medtronic announced FDA clearance of LigaSure RAS Maryland on Hugo, broadening U.S. robotic procedure instruments.
- Oct 7, 2026 · business change
FDA published a Class I recall notice for Bravo capsule delivery devices on September 15. Affected products must be removed and replaced; the notice reports 184 serious injuries and no deaths as of August 10.
- Oct 7, 2026 · business change
Medtronic launched the MiniMed share-exchange offer to complete separation; the October 9 scheduled expiry remained pending.
- Oct 7, 2026 · business change
Medtronic raised FY2027 organic revenue growth guidance to 7.25%-7.75% after its extra-week first quarter.
- Oct 7, 2026 · business change
Medtronic completed the SPR Therapeutics acquisition, adding temporary peripheral nerve stimulation for pain treatment.
- Oct 7, 2026 · business change
Medtronic completed the Scientia Vascular acquisition, adding neurovascular access tools to its therapeutic portfolio.
- Oct 7, 2026 · business change
Medtronic acquired the remaining CathWorks stake, adding wire-free coronary assessment to its cardiovascular portfolio.
- Oct 7, 2026 · business change
MiniMed completed its IPO. Medtronic retained about 90.03%, so Diabetes remained consolidated while separation progressed.
- Oct 7, 2026 · business change
Medtronic decided to exit ventilator products, recording asset and inventory charges and retaining its remaining Acute Care and Monitoring business.
- Oct 7, 2026 · business change
Medtronic signed an IP agreement with Edwards Lifesciences, receiving $265 million of one-time revenue plus future product royalties.
- Oct 7, 2026 · business change
Medtronic contributed half of Renal Care Solutions to the Mozarc joint venture with DaVita, changing its consolidated product scope.
- Oct 7, 2026 · business change
Medtronic sold Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses to Cardinal Health for $6.1 billion, reducing its mature supply portfolio.
- Oct 7, 2026 · analyst revision
Added dated trajectories, management, testable bull and bear arguments, shared market links and current quality risks. Company-wide product integration is not treated as a third-party network effect.
- Oct 7, 2026 · analyst revision
Replaced Q1 FY2027 revenue weights with FY2026 annual weights, removed segment profit weights that excluded group charges, and corrected the FY2026 filing date to June 18. Reclassified procedure training and internal product integration into training and workflow claims; added a limited Medical Surgical consumables claim from the new Hugo instrument clearance.
Industry & peers
Peer map
Hover a point for its values; click a peer to compare. Dashed lines: industry medians.
Global cardiovascular devices
Rhythm management, cardiac ablation and mapping, heart-failure support, vascular intervention and structural-heart devices sold to hospitals and clinicians worldwide. Excludes diabetes devices, drugs, imaging and hospital procedure bills.
- Medtronic
- Abbott
- Boston Scientific
- Johnson & Johnson MedTech
- Edwards Lifesciences
| Stocks | Moat | Gross m. | Op. m. | |
|---|---|---|---|---|
| MDT | 58 | 65.0% | 18.1% | |
| Industry median | 14 | 75 | 52.1% | 13.3% |
| Sector median | 55 | 76 | 61.5% | 17.3% |
| All stocks median | 398 | 76 | 53.1% | 20.0% |
Moat medians cover every stock. Margin medians count only stocks with collected numbers and need at least three.
Drivers & risks
- Aging and cardiovascular disease sustain demand for treatment. Access to trained clinicians limits how fast procedures can expand.
- Pulsed field ablation, leadless pacing and transcatheter valves can expand eligible patients and change supplier share.
- Hospital demand for shorter procedures and recovery can favor effective minimally invasive devices.
- Successful trials, reimbursement and usable clinical workflows turn approvals into recurring procedure sales.
- Reimbursement has a strong effect on newer treatment adoption. Procedure codes and regulatory clearance need payer coverage and trained staff before demand turns into sales.
- Large rivals can displace products with better clinical results, procedure speed or safety; a broad patent portfolio does not establish exclusivity.
- Hospital purchasing groups and reimbursement controls cap realized prices.
- High rates and constrained hospital budgets can delay capital systems; clinician shortages can restrict procedures even when patient demand is strong.
- Tariffs, manufacturing problems, recalls and regulatory requirements raise costs or interrupt supply. Currency translation affects global manufacturers.
- Remote monitoring and mapping software can contain clinically relevant errors. Installed workflows require reliable updates and support; integration alone does not ensure retention.
Bulls & bears
Can Medtronic turn ablation, connected spine systems and new procedure platforms into durable sales and cash earnings after MiniMed separates, while keeping quality costs and hospital price pressure under control?
Arguments
What to watch
- 1Cardiac Ablation Solutions sales and reported competitive share movement
- 2Cranial and Spinal Technologies sales, navigation placements and implant pull-through
- 3Hugo installed systems, procedures and instrument sales
- 4Actual post-exchange shares and issuer-recast continuing earnings
- 5Recall remediation, product availability and litigation costs
- 6Reported operating cash flow, capex and recurring restructuring
Next check: Q2 FY2027 results on November 24: review the continuing-operation recast after MiniMed, actual post-exchange shares, separation taxes and cash costs, then ablation and surgical-platform growth.
Sources: company filings and dated sources collected for Find My Moat; Post-separation shares outstanding have not been verified; market cap and valuation multiples are unavailable. Not investment advice.
Free to reuse, commercially too, with a credit link. See the data license.
Moat Score 58/100 by <a href="https://www.findmymoat.com/stocks/XNYS:MDT">Find My Moat</a> (as of September 2026)Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.